Assignee
iTeos Belgium SA
BE·5 granted patents·16 pending applications·4 citations·filing 2019–2025
Top patents by PatentIndex Score
21 records- 0185US11439705B2Anti-TIGIT antibodiesiTeos Belgium SA·Filed 2019·Granted Sep 13, 2022·3 cites·15 claims
- 0274US2023181731A1Anti-TIGIT AntibodiesiTeos Belgium SA·Filed 2022·Application pending·0 cites
- 0373US11376255B2Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agentsiTeos Belgium SA·Filed 2020·Granted Jul 5, 2022·1 cites·6 claims
- 0473US2023190931A1Anti-TIGIT AntibodiesiTeos Belgium SA·Filed 2022·Application pending·0 cites
- 0568US2026049136A1Anti-trem2 antibodies and methods of useiTeos Belgium SA·Filed 2025·Application pending·0 cites
- 0666US12492255B2Anti-TREM2 antibodies and methods of useiTeos Belgium SA·Filed 2025·Granted Dec 9, 2025·0 cites·25 claims
- 0766US2025101101A1Anti-trem2 antibodies and methods of useiTeos Belgium SA·Filed 2024·Application pending·0 cites
- 0863US2023159564A12-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of CancersiTeos Belgium SA·Filed 2022·Application pending·0 cites
- 0962US11427594B2Non brain penetrant A2A inhibitors and methods for use in the treatment of cancersiTeos Belgium SA·Filed 2019·Granted Aug 30, 2022·0 cites·2 claims
- 1060US2024343735A1Hydrochloride Salt of Inupadenant, Pharmaceutical Compositions and Methods of Use ThereofiTeos Belgium SA·Filed 2024·Application pending·0 cites
- 1158US2024327415A1Multicomponent Complexes, Including Salts, Crystalline Forms, and Hydrates and Solvates of ENT1 InhibitorsiTeos Belgium SA·Filed 2024·Application pending·0 cites
- 1258US2024400581A1Process for Preparing a Macrocyclic Compound Having ENT1 Inhibiting ActivityiTeos Belgium SA·Filed 2024·Application pending·0 cites
- 1355US2023407352A1Method for the Production of Thiocarbamate Derivatives A2AR InhibitorsiTeos Belgium SA·Filed 2021·Application pending·0 cites
- 1455US2024368183A1Macrocyclic Compounds Having ENT1 Inhibiting ActivityiTeos Belgium SA·Filed 2024·Application pending·0 cites
- 1553US2023146675A1PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTSiTeos Belgium SA·Filed 2022·Application pending·0 cites
- 1650US12312401B2Anti-TIGIT antibodiesiTeos Belgium SA·Filed 2020·Granted May 27, 2025·0 cites·20 claims
- 1749US2023121530A1Thiocarbamate derivatives as a2a inhibitors, pharmaceutical composition thereof and combinations with anticancer agentsiTeos Belgium SA·Filed 2022·Application pending·0 cites
- 1846US2023203058A1Macrocyclic diamine derivatives as ent inhibitors for the treatment of cancers, and combination thereof with adenosine receptor antagonistsiTeos Belgium SA·Filed 2021·Application pending·0 cites
- 1944US2024141436A1Compounds, Compositions and Methods of Treatment ThereofiTeos Belgium SA·Filed 2022·Application pending·0 cites
- 2043US2023165863A1Methods and formulations for administration of thiocarbamate deriviatives a2a inhibitorsiTeos Belgium SA·Filed 2021·Application pending·0 cites
- 2142US2021338672A1Use of an inhibitor of an ent family transporter in the treatment of cancer and combination thereof with an adenosine receptor antagonistiTeos Belgium SA·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when iTeos Belgium SA files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →